Table 1 Epidemiological, clinical and biochemical characteristics of 113 patients with end-stage liver disease within a follow-up period of 12 months
Variables | Patient Cohort |
|---|---|
Age [yrs] | 58 (51–63) |
Gender n (%) | |
female | 52 (46.0) |
male | 61 (54.0) |
BMI [kg/m2] | 28.0 (23.9–31.1) |
Aetiology n (%) | |
alcoholic | 51 (45.1) |
cholestatic | 15 (13.3) |
NAFLD | 8 (7.1) |
viral | 13 (11.5) |
others | 26 (23.0) |
Serum albumin [g/L] | 36.2 (32.4–40.9) |
Serum bilirubin [g/dL] | 1.2 (0.7–2.6) |
INR | 1.30 (1.14–1.51) |
Platelet count [/nL] | 111 (75–152) |
Serum creatinine [mg/dL] | 0.88 (0.74–1.24) |
Serum sodium [mmol/L] | 139 (136–141) |
Ascites grade n (%) | |
none/mild | 82 (72.6) |
moderate | 11 (9.7) |
severe | 20 (17.7) |
HE grade n (%) | |
grade 0 | 71 (62.8) |
grade I | 39 (34.5) |
grade II | 2 (1.8) |
grade III | 1 (0.9) |
Oesophageal varices n (%) | |
yes | 77 (68.1) |
no | 35 (31.0) |
unknown | 1 (0.9) |
Previous GI haemorrhage n (%) | 28 (25.7) |
Child-Pugh classes n (%) | |
A | 53 (46.9) |
B | 41 (36.3) |
C | 19 (16.8) |
Fibroscan stiffness [kPa] | 38.5 (20.5–59.3) |
MELD | 12 (9–16) |
MELD-Na | 13 (9–19) |
CreLiMAx score | 0.94 (0.91–0.96) |
LiMAx® [μg/kg/h] | 165 (104–273) |
Underwent LTx n (%) | 11 (9.7) |
Liver-related death n (%) | 13 (11.5) |